JP7208139B2 - 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 - Google Patents

双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 Download PDF

Info

Publication number
JP7208139B2
JP7208139B2 JP2019531623A JP2019531623A JP7208139B2 JP 7208139 B2 JP7208139 B2 JP 7208139B2 JP 2019531623 A JP2019531623 A JP 2019531623A JP 2019531623 A JP2019531623 A JP 2019531623A JP 7208139 B2 JP7208139 B2 JP 7208139B2
Authority
JP
Japan
Prior art keywords
bipolar disorder
mania
bipolar
formula
disorder
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019531623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020502106A5 (enExample
JP2020502106A (ja
Inventor
シン・ユジン
ハン・セミョン
Original Assignee
エスケー バイオファーマスティカルズ カンパニー リミテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エスケー バイオファーマスティカルズ カンパニー リミテッド filed Critical エスケー バイオファーマスティカルズ カンパニー リミテッド
Publication of JP2020502106A publication Critical patent/JP2020502106A/ja
Publication of JP2020502106A5 publication Critical patent/JP2020502106A5/ja
Application granted granted Critical
Publication of JP7208139B2 publication Critical patent/JP7208139B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2019531623A 2016-12-14 2017-12-14 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用 Active JP7208139B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR20160170224 2016-12-14
KR10-2016-0170224 2016-12-14
PCT/KR2017/014740 WO2018111008A1 (ko) 2016-12-14 2017-12-14 양극성 장애의 예방, 경감 또는 치료를 위한 카바메이트 화합물의 용도

Publications (3)

Publication Number Publication Date
JP2020502106A JP2020502106A (ja) 2020-01-23
JP2020502106A5 JP2020502106A5 (enExample) 2021-01-14
JP7208139B2 true JP7208139B2 (ja) 2023-01-18

Family

ID=62559442

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019531623A Active JP7208139B2 (ja) 2016-12-14 2017-12-14 双極性障害の予防、軽減又は治療のためのカルバメート化合物の使用

Country Status (14)

Country Link
US (1) US11571410B2 (enExample)
EP (1) EP3556366B1 (enExample)
JP (1) JP7208139B2 (enExample)
KR (1) KR102635938B1 (enExample)
CN (1) CN110290788A (enExample)
AU (1) AU2017374458B2 (enExample)
BR (1) BR112019011930A2 (enExample)
CL (1) CL2019001618A1 (enExample)
ES (1) ES3054693T3 (enExample)
IL (1) IL267195B2 (enExample)
MX (1) MX2019006940A (enExample)
MY (1) MY199104A (enExample)
WO (1) WO2018111008A1 (enExample)
ZA (1) ZA201903747B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL281559B2 (en) * 2018-09-21 2025-06-01 Sk Biopharmaceuticals Co Ltd (r)-1-phenyl-2-tetrazolyl ethyl carbamate derivatives and formulations comprising same for use in preventing, alleviating, or treating acute stress disorder or post-traumatic stress disorder
CN113242735A (zh) * 2018-09-21 2021-08-10 爱思开生物制药株式会社 使用氨基甲酸酯化合物预防、缓解或治疗并发的癫痫发作
AU2020389425B2 (en) * 2019-11-22 2026-03-05 Sk Biopharmaceuticals Co., Ltd. Oral pharmaceutical composition comprising carbamate compound and preparation method therefor

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520581A (ja) 2004-11-16 2008-06-19 エラン ファーマ インターナショナル リミテッド 注射可能なナノ粒子のオランザピン製剤
JP2008538557A (ja) 2005-04-22 2008-10-30 エスケー ホルディングス カンパニー リミテッド 神経治療アゾール化合物

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID28529A (id) * 1997-08-14 2001-05-31 Hoffmann La Roche Vinileter heterosiklik untuk gangguan neurologi
US6555585B2 (en) 2000-07-21 2003-04-29 Teva Pharmaceutical Industries, Ltd. Use of derivatives of valproic acid and 2-valproenic acid amides for the treatment of mania in bipolar disorder
DE60223506T2 (de) * 2001-02-27 2008-09-18 Ortho-Mcneil Pharmaceutical, Inc. Carbamatverbindungen zur vorbeugung oder behandlung bipolarer erkrankungen
HUP0303243A3 (en) * 2001-02-27 2012-07-30 Ortho Mcneil Pharm Inc Carbamate compounds for use in preventing and treating bipolar disorder
JP2010508354A (ja) * 2006-10-31 2010-03-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ 広汎性発達障害の処置
AU2009348523B2 (en) 2009-06-22 2015-02-26 Sk Biopharmaceuticals Co., Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US8404461B2 (en) 2009-10-15 2013-03-26 SK Biopharmaceutical Co. Ltd. Method for preparation of carbamic acid (R)-1-aryl-2-tetrazolyl-ethyl ester
US9610274B2 (en) 2010-06-30 2017-04-04 Sk Biopharmaceuticals Co., Ltd. Methods for treating bipolar disorder
EP3180329B1 (en) 2014-08-15 2020-03-18 Janssen Pharmaceuticals, Inc. Triazoles as nr2b receptor inhibitors

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2008520581A (ja) 2004-11-16 2008-06-19 エラン ファーマ インターナショナル リミテッド 注射可能なナノ粒子のオランザピン製剤
JP2008538557A (ja) 2005-04-22 2008-10-30 エスケー ホルディングス カンパニー リミテッド 神経治療アゾール化合物

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
抗精神病薬「エビリファイ」新しい適応症「双極性障害における躁症状の改善」および新剤形「エビリファイOD錠」が承認 [online]，大塚製薬株式会社ホームページ，2012年01月18日，[検索日2021.10.05], インターネット<URL: https://www.otsuka.co.jp/company/newsreleases/2012/20120118_01.html>

Also Published As

Publication number Publication date
US20190314337A1 (en) 2019-10-17
IL267195B1 (en) 2024-01-01
AU2017374458A1 (en) 2019-07-04
ES3054693T3 (en) 2026-02-05
AU2017374458B2 (en) 2023-03-02
BR112019011930A2 (pt) 2019-10-29
US11571410B2 (en) 2023-02-07
JP2020502106A (ja) 2020-01-23
WO2018111008A1 (ko) 2018-06-21
CA3046297A1 (en) 2018-06-21
EP3556366B1 (en) 2025-10-22
CL2019001618A1 (es) 2019-08-23
RU2019121913A (ru) 2021-01-15
EP3556366A4 (en) 2020-06-17
IL267195B2 (en) 2024-05-01
KR102635938B1 (ko) 2024-02-13
MX2019006940A (es) 2019-09-06
ZA201903747B (en) 2021-01-27
RU2019121913A3 (enExample) 2021-04-21
KR20190087572A (ko) 2019-07-24
CN110290788A (zh) 2019-09-27
EP3556366A1 (en) 2019-10-23
MY199104A (en) 2023-10-13
IL267195A (enExample) 2019-07-31

Similar Documents

Publication Publication Date Title
BRPI0618239A2 (pt) uso de flibanserina para o tratamento de distúrbios de desejo sexual pré-menopáusico
JP7071287B2 (ja) 繊維筋痛又は繊維筋痛の関連する機能的症候群を予防又は治療するためのカルバメート化合物の使用
WO2008006839A2 (en) Combinations of flibanserin with caffeine, process for their preparation and use thereof as medicaments
MX2013010384A (es) Composiciones y sus usos para tratar hiperucemia y transtornos metabolicos asociados con hiperucemia.
US20130150346A1 (en) Use of FAAH Inhibitors for Treating Parkinson&#39;s Disease and Restless Legs Syndrome
JP2022507533A (ja) 肺動脈性高血圧症および他疾患に関連する肺動脈性肺高血圧症の治療法
JP2018203774A (ja) 精神障害の治療における使用のためのイロペリドン代謝物
US11571410B2 (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder
US20200223838A1 (en) Methods of use of phenoxypropylamine compounds to treat depression
JP6960415B2 (ja) 三叉神経痛を予防又は治療する目的のためのカルバメート化合物の使用
JP7417595B2 (ja) てんかん重積状態の予防、軽減又は治療のためのカルバメート化合物の使用
JP2012508186A (ja) むずむず脚症候群および睡眠障害の治療
TWI864376B (zh) 焦慮症處置用組成物及處置方法
JP7408643B2 (ja) カルバメート化合物及びそれを含む製剤の急性ストレス障害又は心的外傷後ストレス障害の予防、軽減又は治療のための使用
RU2774970C2 (ru) Применение карбаматных соединений для профилактики, облегчения или лечения биполярного расстройства
JP7369185B2 (ja) カルバメート化合物の糖尿病性末梢神経障害又は化学療法剤誘発性末梢神経障害の予防、緩和又は治療のための使用
CN111973615A (zh) 一种治疗躁狂型精神障碍及精神分裂症的药物
HK40015213A (en) Use of carbamate compounds for prevention, alleviation or treatment of bipolar disorder

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201124

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220117

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220322

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220705

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20221003

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221205

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221220

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20230105

R150 Certificate of patent or registration of utility model

Ref document number: 7208139

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250